AstraZeneca partners with Insitro for AI-driven drug discovery, deal valued up to $1.5B
AstraZeneca has partnered with Insitro for AI-enabled drug discovery, focusing on identifying new targets for liver and heart diseases. While multiple outlets report the deal could be valued up to $1.5 billion, one source highlights an initial payment of $40 million. This collaboration, announced by the companies, leverages Insitro's AI platform for target identification.
4 articles from 4 outlets covered this story. Their coverage differs on 1 point. The underlying claim is sourced from a press release.
What do all outlets agree on?
4 outlets covered “AstraZeneca partners with Insitro for AI-driven drug discovery, deal valued up to $1.5B”. All of them report the following:
- AstraZeneca partnered with Insitro
- Partnership for AI-enabled drug discovery
- Focus on liver and heart diseases (MASH, cardio)
- Aims for target discovery
Did outlets disagree about this?
Yes. Coverage of “AstraZeneca partners with Insitro for AI-driven drug discovery, deal valued up to $1.5B” differs on 1 point. Each account below is how a different outlet described the same event:
The reported value of the deal
Which figures do outlets report differently?
1 figure in this story is reported with conflicting values:
Which outlets covered this?
All 4 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.